StrategyR - A Trademark of Global Industry Analysts, Inc.
Project Edition: 7
Domain Experts Featured: 8
Abstract:
Global Epinephrine Autoinjectors Market to Reach $3.6 Billion by 2030
The global market for Epinephrine Autoinjectors estimated at US$2.5 Billion in the year 2023, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2023-2030. The 0.15 gm Dosage Epinephrine Autoinjectors, one of the segments analyzed in the report, is expected to record 4.6% CAGR and reach US$2.5 Billion by the end of the analysis period. Growth in the 0.30 gm Dosage Epinephrine Autoinjectors segment is estimated at 5.6% CAGR for the next 8-year period.
The U.S. Market is Estimated at $756.1 Million, While China is Forecast to Grow at 4.5% CAGR
The Epinephrine Autoinjectors market in the U.S. is estimated at US$756.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$634.5 Million by the year 2030 trailing a CAGR of 4.5% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.6% and 3.8% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.
Introducing Our Exciting New Report Features for 2024
» Full access to influencer engagement stats
» Free access to digital archives & "MarketGlass" research platform. The proprietary platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. The state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.
» Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities
» Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas
» Complimentary report updates for one year
» Competitor coverage with global market shares of major players
» Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies
» Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes
What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.
- ALK-Abello A/S
- Bausch + Lomb UK Ltd- Emerade
- Teva Pharmaceutical Industries Ltd.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the The 0.15 gm Dosage Epinephrine Autoinjectors segment, which is expected to reach US$2.5 Billion by 2030 with a CAGR of 4.6%. The 0.30 gm Dosage Epinephrine Autoinjectors segment is also set to grow at 5.6% CAGR for the next 8-year period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $756.1 Million in 2023, and China, forecasted to grow at an impressive 4.5% CAGR to reach $634.5 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Epinephrine Autoinjectors Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Epinephrine Autoinjectors Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Epinephrine Autoinjectors Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as ALK-Abello A/S, Bausch + Lomb UK Ltd- Emerade, Teva Pharmaceutical Industries Ltd., and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 44 Featured):
- ALK-Abello A/S
- Bausch + Lomb UK Ltd- Emerade
- Teva Pharmaceutical Industries Ltd.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ALK-Abello A/S
- Bausch + Lomb UK Ltd- Emerade
- Teva Pharmaceutical Industries Ltd.
